Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.

Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.

Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.

The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.

Herbal compound formulations using herbs curcuma longa (turmeric), ocimum sanctum (holy basil) and emblica officinalis (amla) in their natural forms and a method of packaging the same for dietary supplement as tablets, wafers, capsules and as teabags where the packaging of individual dosages and the outer packaging may use visual display of color that represents the proportion and presence of different herbs in the herbal compound.

The invention relates to the use of a composition comprising at least one extract of propolis, having at least one of the following properties:—an antioxidant value (ORAC) greater than or equal to 500 mmol TE/100 g of dry extract,—a flavones and flavonols content greater than or equal to 5.5% by weight with respect to the total weight of dry material of the extract,—a flavanones and dihydroflavanols content greater than or equal to 5% by weight with respect to the total weight of dry material of the product, in order to prevent and/or limit the side effects of chemotherapy.

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.

The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions.

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.